Past, present, and future for biologic intervention in atopic dermatitis

被引：41

作者：

Howell, M. D. ^{[1
]}

Parker, M. L. ^{[1
]}

Mustelin, T. ^{[1
]}

Ranade, K. ^{[1
]}

机构：

[1] MedImmune LLC, Gaithersburg, MD 20878 USA

来源：

ALLERGY | 2015年 / 70卷 / 08期

关键词：

atopic dermatitis; basic mechanisms; clinical immunology; dermatology; quality of life; THYMIC STROMAL LYMPHOPOIETIN; ANTI-CD20 RITUXIMAB TREATMENT; ALPHA-CHAIN GENE; T-CELLS; STAPHYLOCOCCUS-AUREUS; TH2; CYTOKINES; FILAGGRIN MUTATIONS; SIGNAL TRANSDUCER; PROMOTER REGION; IGE ANTIBODIES;

D O I：

10.1111/all.12632

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

Atopic dermatitis (AD) is a debilitating disease that significantly alters the quality of life for one in four children and one in 10 adults. Current management of AD utilizes combinations of treatments to symptomatically alleviate disease by suppressing the inflammatory response and restoring barrier function in the skin, reducing disease exacerbation and flare, and preventing secondary skin infections. Resolution is temporary and long-term usage of these treatments can be associated with significant side-effects. Antibody therapies previously approved for inflammatory diseases have been opportunistically evaluated in patients with atopic dermatitis; however, they often failed to demonstrate a significant clinical benefit. Monoclonal antibodies currently in development offer hope to those individuals suffering from the disease by specifically targeting immune and molecular pathways important for the pathogenesis of atopic dermatitis. Here, we review the underlying biological pathways and the state of the art in therapeutics in AD.

引用

页码：887 / 896

页数：10

共 123 条

[51] Immunologic Effects of Omalizumab in Children with Severe Refractory Atopic Dermatitis: A Randomized, Placebo-Controlled Clinical Trial [J].